Skip to main content
SpringerLink
Log in

Pharmacologic Strategies to Preserve Renal Function in Acute Decompensated Heart Failure

  • Pharmacologic Therapy (WHW Tang, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Over a million patients get hospitalized with the diagnosis of acute decompensated heart failure which poses an insurmountable financial burden on the health care system. Heart failure alone incurs over 30 billion dollars with half the cost spent towards acute hospitalizations. Majority of the treatment strategies have focused towards decongesting patients which often comes with the cost of worsening renal function. Renal dysfunction in the setting of acute decompensated heart failure portends worse morbidity and mortality. Recently, there has been a change in the focus with shift towards therapies attempting to conserve renal function. In the past decade, we have witnessed several large randomized controlled trials testing the established as well as emerging therapies in this subset of population with mixed results. This review intends to provide a comprehensive overview of the pharmacologic therapies commonly utilized in the management of acute decompensated heart failure and the body of evidence supporting these strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statisticsd2012 update:a report from the American Heart Association. Circulation. 2012;125:e2e220.

    Google Scholar 

  2. Dupont M, Mullens W, Finucan M, et al. Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment. Eur J Heart Fail. 2013;15:433–40.

    Article  CAS  PubMed  Google Scholar 

  3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2013;3.

  4. Lindenfeld J, Albert NM, Boehmer JP, et al. Heart Failure Society of America. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16(6):e1–194.

    Article  PubMed  Google Scholar 

  5. Adams Jr KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–16.

    Article  PubMed  Google Scholar 

  6. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167:1493e502.

    Article  Google Scholar 

  7. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103(1):1–6.

    Article  CAS  PubMed  Google Scholar 

  8. Emerman CL, Marco TD, Costanzo MR, et al. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE(R) Registry. J Card Fail. 2004;10(Suppl):S116–7.

    Article  Google Scholar 

  9. Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med. 1991;115:360–6.

    Article  CAS  PubMed  Google Scholar 

  10. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797e805. Large randomized trial testing the doing and route of loop ndiuretic administration.

    Article  Google Scholar 

  11. Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2013. doi:10.1161/ CIRCHEARTFAILURE.113.000895. Novel study evaluating a new metric of testing diuretic response in ADHF patients.

    Google Scholar 

  12. Valente MA, Voors AA, Damman K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014;35(19):1284–93.

    Article  CAS  PubMed  Google Scholar 

  13. Verbrugge FH, Dupont M, Shao Z, et al. Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failure. J Card Fail. 2013;19(9):621–8. Compareative analysis of novel urinary biomarkers in ADHF population.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary edema. Lancet. 1998;351:389–93.

    Article  CAS  PubMed  Google Scholar 

  15. Hockings BE, Cope GD, Clarke GM, Taylor RR. Randomized controlled trial of vasodilator therapy after myocardial infarction. Am J Cardiol. 1981;48:345e52.

    Article  Google Scholar 

  16. Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med. 1982;306:1129e35.

    Google Scholar 

  17. Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008;52:200e7.

    Article  Google Scholar 

  18. Colucci WS, Elkayam U, Horton DP, et al. Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246e53.

    Article  Google Scholar 

  19. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531e40.

    Google Scholar 

  20. Sackner-Bernstein JD, Kowalski M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900e5.

    Article  Google Scholar 

  21. O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32e43. Landmark trial testing efficacy of Nesiritide in ADHF patients.

    Google Scholar 

  22. Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation. 2008;117(2):200–5.

    Article  CAS  PubMed  Google Scholar 

  23. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail. 2010;16(12):922–30.

    Article  CAS  PubMed  Google Scholar 

  24. Triposkiadis FK, Butler J, Karayannis G, et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. Int J Cardiol. 2014;172:115–21.

    Article  PubMed  Google Scholar 

  25. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction The ROSE acute heart failure randomized trial. JAMA. 2013;310(23):2533–43.

    CAS  PubMed Central  PubMed  Google Scholar 

  26. Gheorghiade M, Gattis WA, O’Connor CM, et al. Acute and chronic therapeutic impact of a vasopressin antagonist in congestive heart failure (ACTIV in CHF) investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV). JAMA. 2004;291:1963–71.

    Article  CAS  PubMed  Google Scholar 

  27. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA. 2007;297:1319–31.

    Article  CAS  PubMed  Google Scholar 

  28. Givertz MM, Massie BM, Fields TK, et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007;50:1551e60.

    Article  Google Scholar 

  29. Voors AA, Dittrich HC, Massie BM, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction. J Am Coll Cardiol. 2011;57:1899–907.

  30. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-fi nding phase IIb study. Lancet. 2009;373:1429–39.

    Article  CAS  PubMed  Google Scholar 

  31. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29–39.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Sachin Kumar and David O. Taylor declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Sachin Kumar & David O. Taylor

Authors
  1. Sachin Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David O. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David O. Taylor.

Additional information

This article is part of the Topical Collection on Pharmacologic Therapy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kumar, S., Taylor, D.O. Pharmacologic Strategies to Preserve Renal Function in Acute Decompensated Heart Failure. Curr Heart Fail Rep 12, 1–6 (2015). https://doi.org/10.1007/s11897-014-0239-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-014-0239-z

Keywords

Search

Navigation